TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.

Tibet Rhodiola Pharmaceutical Holding Co.

600211

CNE000000ZW7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
38.7 ^CNY	-0.90%		-4.14%	+3.09%

Apr. 26	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 26	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange Health Care Sector Index

December 10, 2021 at 12:00 am EST

Tibet Rhodiola Pharmaceutical Holding Co. has been removed from Shanghai Stock Exchange Health Care Sector Index.

Latest news about Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co.	Jan. 13	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Tibet Rhodiola Pharma Unit Becomes Authorized Marketer of Heart Drug	23-02-06	MT
Tibet Rhodiola Pharma Sees 81% Jump in 2022 Profit	23-01-26	MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Tibet Rhodiola Pharma Wins License to Produce Chest Pain Tablets	22-09-26	MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange A Share Index	22-05-09	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange A Share Index	22-05-05	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange Health Care Sector Index	21-12-10	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tibet Rhodiola Pharmaceutical Holding Co.(XSSC:600211) added to S&P Global BMI Index	21-09-20	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-16	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange Health Care Sector Index	21-06-14	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-11	CI
Tibet Rhodiola Pharmaceutical : Stemirna COVID-19 vaccine candidate obtains clinical trial approval in China	21-01-04	RE
Shanghai Fosun Pharmaceutical : Fosun Pharma to buy 100 million doses of BioNTech's COVID-19 vaccine for mainland China	20-12-15	RE

Chart Tibet Rhodiola Pharmaceutical Holding Co.

Duration

Period

Chart Tibet Rhodiola Pharmaceutical Holding Co.

More charts

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tibet Rhodiola Pharmaceutical Holding Co.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.7

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.	+3.09%	1.72B
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+31.87%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.31%	240B
NOVARTIS AG	+9.33%	209B
ROCHE HOLDING AG	-9.28%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals